

**UNITED STATES SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

Date of report: January 6, 2025

Commission File Number: 001-38974

BIOPHYTIS S.A.

(Translation of registrant's name into English)

**Stanislas Veillet
Biophytis S.A.
Sorbonne University-BC 9, Bâtiment A 4ème étage
4 place Jussieu
75005 Paris, France
+33 1 44 27 23 00**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F ☐ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

On January 6, 2025, Biophytis S.A. (the “Company”) issued a press release announcing the temporary suspension of the listing of its ordinary shares and share warrants on the Euronext Growth market.

EXHIBIT LIST

Exhibit	Description
<u>99.1</u>	<u>Press Release dated January 6, 2025</u>

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BIOPHYTIS S.A.

Date: January 6, 2025

By:

Name: Stanislas Veillet

Title: Chairman and Chief Executive Officer